DK2540843T3 - Genetiske polymorfismer ved aldersbetinget makulær degeneration - Google Patents

Genetiske polymorfismer ved aldersbetinget makulær degeneration

Info

Publication number
DK2540843T3
DK2540843T3 DK12185155.4T DK12185155T DK2540843T3 DK 2540843 T3 DK2540843 T3 DK 2540843T3 DK 12185155 T DK12185155 T DK 12185155T DK 2540843 T3 DK2540843 T3 DK 2540843T3
Authority
DK
Denmark
Prior art keywords
age
macular degeneration
related macular
genetic polymorphisms
polymorphisms
Prior art date
Application number
DK12185155.4T
Other languages
Danish (da)
English (en)
Inventor
Robert R Graham
Timothy W Behrens
Tsontcho Ianchulev
Howard Shapiro
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2540843T3 publication Critical patent/DK2540843T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6846Common amplification features
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00Reactions of nucleic acids characterised by
    • C12Q2531/10Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113PCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00Reactions of nucleic acids characterised by
    • C12Q2531/10Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/137Ligase Chain Reaction [LCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK12185155.4T 2008-11-05 2009-11-05 Genetiske polymorfismer ved aldersbetinget makulær degeneration DK2540843T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11166708P 2008-11-05 2008-11-05
US17485609P 2009-05-01 2009-05-01
EP09748682A EP2356250A2 (en) 2008-11-05 2009-11-05 Genetic polymorphisms in age-related macular degeneration

Publications (1)

Publication Number Publication Date
DK2540843T3 true DK2540843T3 (da) 2014-09-01

Family

ID=41650496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12185155.4T DK2540843T3 (da) 2008-11-05 2009-11-05 Genetiske polymorfismer ved aldersbetinget makulær degeneration

Country Status (14)

Country Link
US (2) US20120003641A1 (enExample)
EP (2) EP2540843B1 (enExample)
JP (1) JP5701216B2 (enExample)
KR (1) KR101719376B1 (enExample)
CN (2) CN103333952B (enExample)
AU (1) AU2009313475B2 (enExample)
CA (1) CA2740242A1 (enExample)
DK (1) DK2540843T3 (enExample)
ES (1) ES2498274T3 (enExample)
IL (1) IL211995A (enExample)
MX (1) MX2011004763A (enExample)
PL (1) PL2540843T3 (enExample)
SI (1) SI2540843T1 (enExample)
WO (1) WO2010054110A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
RU2486253C2 (ru) 2008-07-25 2013-06-27 Инфоком Корпорейшн Онкоген nrf2 и его применение
US20130330341A1 (en) * 2011-02-23 2013-12-12 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
JP6040227B2 (ja) 2011-05-19 2016-12-07 アジーナ バイオサイエンス, インコーポレイテッド マルチプレックス核酸同定のための製品およびプロセス
WO2013030032A1 (en) * 2011-08-26 2013-03-07 F. Hoffmann-La Roche Ag A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
BR112014008862A2 (pt) * 2011-10-14 2018-08-07 Genentech Inc anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
WO2016100745A2 (en) * 2014-12-19 2016-06-23 Children's Hospital Medical Center Methods and compositions related to transplant-associated thrombotic microangiopathy
AU2016250841A1 (en) 2015-04-24 2017-11-02 Agena Bioscience, Inc. Multiplexed method for the identification and quantitation of minor alleles and polymorphisms
CN104878105B (zh) * 2015-06-02 2017-10-31 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂
CN104894261B (zh) * 2015-06-02 2020-02-14 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN115951066A (zh) * 2016-02-29 2023-04-11 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
PL3472149T3 (pl) 2016-06-21 2024-02-12 Orion Ophthalmology LLC Heterocykliczne pochodne prolinamidu
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113373236B (zh) * 2021-02-19 2021-12-31 中国科学院北京基因组研究所(国家生物信息中心) 一种获得中国人群个体年龄的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
WO1999013108A1 (en) 1997-09-10 1999-03-18 University Of Maryland, Baltimore Method of amplifying dna and rna mismatch cleavage products
JP2008520242A (ja) * 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration

Also Published As

Publication number Publication date
JP5701216B2 (ja) 2015-04-15
SI2540843T1 (sl) 2014-10-30
US20120003641A1 (en) 2012-01-05
WO2010054110A3 (en) 2010-08-19
AU2009313475A1 (en) 2010-05-14
MX2011004763A (es) 2011-06-01
CN102203296B (zh) 2014-12-03
WO2010054110A2 (en) 2010-05-14
IL211995A (en) 2014-04-30
JP2012507988A (ja) 2012-04-05
HK1173751A1 (en) 2013-05-24
CN103333952B (zh) 2015-07-29
AU2009313475B2 (en) 2016-06-02
CN103333952A (zh) 2013-10-02
US20170159114A1 (en) 2017-06-08
CN102203296A (zh) 2011-09-28
CA2740242A1 (en) 2010-05-14
EP2540843A2 (en) 2013-01-02
EP2540843B1 (en) 2014-07-02
EP2540843A3 (en) 2013-05-29
BRPI0914368A2 (pt) 2015-10-20
ES2498274T3 (es) 2014-09-24
KR20110081836A (ko) 2011-07-14
EP2356250A2 (en) 2011-08-17
KR101719376B1 (ko) 2017-03-23
PL2540843T3 (pl) 2014-12-31
IL211995A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DK2540843T3 (da) Genetiske polymorfismer ved aldersbetinget makulær degeneration
EP2227780A4 (en) GENETIC ANALYSIS
IL247144A (en) Multiple genetic occurrences of age-dependent staining
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
HUE041436T2 (hu) Tal-effektor-közvetített DNS-módosítás
EP2370575A4 (en) TARGETED INTEGRATION IN THE ZP15 POSITION
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
GB0815109D0 (en) Polydialkylsiloxane-bridged bi-photochromic molecules
BRPI0907819A2 (pt) filtros
PL2274353T3 (pl) Polikarbodiimidy
PL2145914T3 (pl) Preparaty plastyfikatorów
IL193396A0 (en) Variants in complement regulatory genes predict age-related macular degeneration
EP2330314A4 (en) FRONT FORKS
PT1991529E (pt) Arilsulfonamidas substituídas como produtos antivirais
EP2292798A4 (en) HYBRIDIZATION IN SITU D ARN
IL210704A0 (en) Nonimmunosuppresive cyclosporine analogue molecules
EP2169142A4 (en) METHOD FOR MANUFACTURING FLOOR
EP2249871A4 (en) OPHTHALMIC COMPOSITION
GB2466379B (en) Protein stabilizer
IL238819A (en) Methods to produce viruses
BRPI0911311A2 (pt) titano silicato
GB0816702D0 (en) Complement proteins
ATE486820T1 (de) Glaspostenverteilung
GB0903562D0 (en) RNA molecules
GB0716947D0 (en) Genetic analysis